UNC 2400negative control of UNC1999 CAS# 1433200-49-7 |
- AZ505 ditrifluoroacetate
Catalog No.:BCC4265
CAS No.:1035227-44-1
- UNC0638
Catalog No.:BCC1135
CAS No.:1255580-76-7
- EPZ005687
Catalog No.:BCC2219
CAS No.:1396772-26-1
- UNC0379
Catalog No.:BCC8055
CAS No.:1620401-82-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1433200-49-7 | SDF | Download SDF |
PubChem ID | 91691116 | Appearance | Powder |
Formula | C35H47N7O2 | M.Wt | 597.79 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 100 mM in 1eq. HCl | ||
Chemical Name | N-[(1,6-dimethyl-2-oxo-4-propylpyridin-3-yl)methyl]-N-methyl-1-propan-2-yl-6-[6-(4-propan-2-ylpiperazin-1-yl)pyridin-3-yl]indazole-4-carboxamide | ||
SMILES | CCCC1=C(C(=O)N(C(=C1)C)C)CN(C)C(=O)C2=C3C=NN(C3=CC(=C2)C4=CN=C(C=C4)N5CCN(CC5)C(C)C)C(C)C | ||
Standard InChIKey | IFSQHIRDVVFJSQ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C35H47N7O2/c1-9-10-26-17-25(6)39(8)35(44)31(26)22-38(7)34(43)29-18-28(19-32-30(29)21-37-42(32)24(4)5)27-11-12-33(36-20-27)41-15-13-40(14-16-41)23(2)3/h11-12,17-21,23-24H,9-10,13-16,22H2,1-8H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Negative control of UNC 1999. Exhibits 1000-fold lower potency than active analog (IC50 values are 62 and >200 μM for EZH1 and EZH2, respectively). |
UNC 2400 Dilution Calculator
UNC 2400 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.6728 mL | 8.3641 mL | 16.7283 mL | 33.4566 mL | 41.8207 mL |
5 mM | 0.3346 mL | 1.6728 mL | 3.3457 mL | 6.6913 mL | 8.3641 mL |
10 mM | 0.1673 mL | 0.8364 mL | 1.6728 mL | 3.3457 mL | 4.1821 mL |
50 mM | 0.0335 mL | 0.1673 mL | 0.3346 mL | 0.6691 mL | 0.8364 mL |
100 mM | 0.0167 mL | 0.0836 mL | 0.1673 mL | 0.3346 mL | 0.4182 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
UNC 2400, a close analogue of UNC1999, is a negative control of UNC1999 that inhibits EZH2 and EZH1 [1].
Histone-lysine N-methyltransferase (EZH1 or EZH2) is the catalytic subunit of the polycomb repressive complex 2 that catalyzes methylation of histone H3 lysine 27 (H3K27). The trimethylation of H3K27 (H3K27me3) is a transcriptionally repressive post-translational modification. Hypertrimethylation of H3K27 and overexpression of EZH2 are involved in cancers [1].
UNC 2400 is a negative control of UNC1999. UNC 2400 inhibited EZH2 with IC50 value of 13 µM and exhibited >1,000-fold less potency than UNC1999. Also, UNC 2400 inhibited EZH1 and EZH2 Y641F with IC50 values of 62 and >200 µM, respectively. In MCF10A cells, UNC 2400 exhibited little inhibition of H3K27me3 levels and had low cellular toxicity with EC50 value of 27.5 µM that was similar to UNC1999. In DB cells, UNC 2400 (3 µM) did not significantly inhibit DB cell proliferation and had no influence on H3K27me3 or EZH2 levels [1].
Reference:
[1]. Konze KD, Ma A, Li F, et al. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol, 2013, 8(6): 1324-1334.
- Ac-YVAD-CHO
Catalog No.:BCC4021
CAS No.:143313-51-3
- H-Chg-OH
Catalog No.:BCC3162
CAS No.:14328-51-9
- RA-XI
Catalog No.:BCN3514
CAS No.:143277-27-4
- AGI-6780
Catalog No.:BCC1331
CAS No.:1432660-47-3
- LDN-212854
Catalog No.:BCC5330
CAS No.:1432597-26-6
- Tin protoporphyrin IX dichloride
Catalog No.:BCC6776
CAS No.:14325-05-4
- Microstegiol
Catalog No.:BCN3157
CAS No.:143246-41-7
- (-)-Isolariciresinol 9'-O-glucoside
Catalog No.:BCN7708
CAS No.:143236-04-8
- (-)-Lyoniresinol 9'-O-glucoside
Catalog No.:BCN7037
CAS No.:143236-02-6
- Z-2-Nal-OH
Catalog No.:BCC3291
CAS No.:143218-10-4
- Dehydroadynerigenin beta-neritrioside
Catalog No.:BCN4706
CAS No.:143212-60-6
- 7-Geranyloxy-5-methoxycoumarin
Catalog No.:BCN5806
CAS No.:1432075-68-7
- RS 56812 hydrochloride
Catalog No.:BCC6877
CAS No.:143339-12-2
- SMIP004
Catalog No.:BCC1955
CAS No.:143360-00-3
- Bryostatin 3
Catalog No.:BCC5620
CAS No.:143370-84-7
- Naratriptan
Catalog No.:BCC5053
CAS No.:143388-64-1
- SAR131675
Catalog No.:BCC5097
CAS No.:1433953-83-3
- (Arg)9 peptide
Catalog No.:BCC5336
CAS No.:143413-47-2
- Poriol
Catalog No.:BCN6816
CAS No.:14348-16-4
- Cnidilin
Catalog No.:BCN2731
CAS No.:14348-22-2
- 5,8-Dihydroxypsoralen
Catalog No.:BCC8104
CAS No.:14348-23-3
- LOE 908 hydrochloride
Catalog No.:BCC7327
CAS No.:143482-60-4
- Emtricitabine
Catalog No.:BCC3774
CAS No.:143491-57-0
- Dammarenediol II
Catalog No.:BCN6240
CAS No.:14351-29-2
Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.[Pubmed:25395428]
Blood. 2015 Jan 8;125(2):346-57.
Enhancer of zeste homolog 2 (EZH2) and related EZH1 control gene expression and promote tumorigenesis via methylating histone H3 at lysine 27 (H3K27). These methyltransferases are ideal therapeutic targets due to their frequent hyperactive mutations and overexpression found in cancer, including hematopoietic malignancies. Here, we characterized a set of small molecules that allow pharmacologic manipulation of EZH2 and EZH1, which include UNC1999, a selective inhibitor of both enzymes, and UNC2400, an inactive analog compound useful for assessment of off-target effect. UNC1999 suppresses global H3K27 trimethylation/dimethylation (H3K27me3/2) and inhibits growth of mixed lineage leukemia (MLL)-rearranged leukemia cells. UNC1999-induced transcriptome alterations overlap those following knockdown of embryonic ectoderm development, a common cofactor of EZH2 and EZH1, demonstrating UNC1999's on-target inhibition. Mechanistically, UNC1999 preferentially affects distal regulatory elements such as enhancers, leading to derepression of polycomb targets including Cdkn2a. Gene derepression correlates with a decrease in H3K27me3 and concurrent gain in H3K27 acetylation. UNC2400 does not induce such effects. Oral administration of UNC1999 prolongs survival of a well-defined murine leukemia model bearing MLL-AF9. Collectively, our study provides the detailed profiling for a set of chemicals to manipulate EZH2 and EZH1 and establishes specific enzymatic inhibition of polycomb repressive complex 2 (PRC2)-EZH2 and PRC2-EZH1 by small-molecule compounds as a novel therapeutics for MLL-rearranged leukemia.
An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.[Pubmed:23614352]
ACS Chem Biol. 2013;8(6):1324-34.
EZH2 or EZH1 is the catalytic subunit of the polycomb repressive complex 2 that catalyzes methylation of histone H3 lysine 27 (H3K27). The trimethylation of H3K27 (H3K27me3) is a transcriptionally repressive post-translational modification. Overexpression of EZH2 and hypertrimethylation of H3K27 have been implicated in a number of cancers. Several selective inhibitors of EZH2 have been reported recently. Herein we disclose UNC1999, the first orally bioavailable inhibitor that has high in vitro potency for wild-type and mutant EZH2 as well as EZH1, a closely related H3K27 methyltransferase that shares 96% sequence identity with EZH2 in their respective catalytic domains. UNC1999 was highly selective for EZH2 and EZH1 over a broad range of epigenetic and non-epigenetic targets, competitive with the cofactor SAM and non-competitive with the peptide substrate. This inhibitor potently reduced H3K27me3 levels in cells and selectively killed diffused large B cell lymphoma cell lines harboring the EZH2(Y641N) mutant. Importantly, UNC1999 was orally bioavailable in mice, making this inhibitor a valuable tool for investigating the role of EZH2 and EZH1 in chronic animal studies. We also designed and synthesized UNC2400, a close analogue of UNC1999 with potency >1,000-fold lower than that of UNC1999 as a negative control for cell-based studies. Finally, we created a biotin-tagged UNC1999 (UNC2399), which enriched EZH2 in pull-down studies, and a UNC1999-dye conjugate (UNC2239) for co-localization studies with EZH2 in live cells. Taken together, these compounds represent a set of useful tools for the biomedical community to investigate the role of EZH2 and EZH1 in health and disease.